BMJ  2004;328:280-282 (31 January), doi:10.1136/bmj.328.7434.280

Education and debate

Antiretroviral therapy in Africa

¹ MRC Laboratories, PO Box 273, Banjul, Gambia, West Africa

We should stop and think about the risks of resistance, and ways of minimising them, before increasing access to antiretroviral therapy in Africa

The first 150 words of the full text of this article appear below.

Demands for the introduction of antiretroviral therapy into Africa have been growing over the past few years. On the face of it, the availability of antiretroviral therapy at what seems to be an affordable price is good news. The treatment can produce dramatic clinical improvements in people with symptomatic HIV disease and, when used optimally, can delay the progression of disease. However, the potential short term gains from reducing individual morbidity and mortality may be far outweighed by the potential for the long term spread of drug resistance if the experience of adherence to treatment for tuberculosis is repeated. Without due forethought and planning, antiretroviral therapy is likely to be introduced to Africa in a random and haphazard way, with inconsistent prescribing practices and poor monitoring of therapy and adherence. This risks the rapid development and transmission of drug resistance.

HIV drug resistance

Virus strains with reduced sensitivity to zidovudine, the first drug . . . [Full text of this article]

-->

Implications of resistance

Drug regimen compliance in Africa

Difficulties of antiretroviral programmes

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Western and traditional African medicine—working together on AIDS

Neil Andersson
BMJ 2005 331: 785. [Extract] [Full Text]

Access to antiretroviral treatment in Africa

Rene Loewenson and David McCoy
BMJ 2004 328: 241-242. [Extract] [Full Text] [PDF]

Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials

Yazdan Yazdanpanah, Daouda Sissoko, Matthias Egger, Yves Mouton, Marcel Zwahlen, and Geneviève Chêne
BMJ 2004 328: 249. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Andersson, N. (2005). Western and traditional African medicine--working together on AIDS. BMJ 331: 785-785 [Full text]  
• Hanson, S. (2005). Is HIV control in sub-Saharan Africa losing focus?: The need for simplified, prioritized prevention strategies. Scand J Public Health 33: 233-235  
• McCoy, D., Chopra, M., Loewenson, R., Aitken, J.-M., Ngulube, T., Muula, A., Ray, S., Kureyi, T., Ijumba, P., Rowson, M. (2005). Expanding Access to Antiretroviral Therapy in Sub-Saharan Africa: Avoiding the Pitfalls and Dangers, Capitalizing on the Opportunities. Am. J. Public Health 95: 18-22 [Abstract] [Full text]  
• Furber, A. S, Hodgson, I. J, Desclaux, A., Mukasa, D. S (2004). Barriers to better care for people with AIDS in developing countries. BMJ 329: 1281-1283 [Full text]  
• Harries, A. D, Libamba, E., Schouten, E. J, Mwansambo, A., Salaniponi, F. M, Mpazanje, R. (2004). Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis. BMJ 329: 1163-1166 [Full text]  
• Loewenson, R., McCoy, D. (2004). Access to antiretroviral treatment in Africa. BMJ 328: 241-242 [Full text]  

Rapid Responses:

Read all Rapid Responses

The continuing doom's day propaganda

Chikwe Ihekweazu
bmj.com, 3 Feb 2004 [Full text]

Antiretroviral therapy in Africa: "learning while doing"

Anthony D Harries
bmj.com, 4 Feb 2004 [Full text]

Insufficient evidence for poor adherence in Africa

H.Florian Neuhann, et al.
bmj.com, 5 Feb 2004 [Full text]

Insufficient evidence for poor adherence in Africa

Catherine J Orrell, et al.
bmj.com, 6 Feb 2004 [Full text]

International Double Standards for Adherence and Development of HIV Drug Resistance

David R. Bangsberg
bmj.com, 17 Feb 2004 [Full text]